3 Complex Generics and Oncology Drug Maker, Ready to Eat Indian Meals Maker and Decorative Auto Parts Maker Stocks With a Strong Future Roadmap: Natco Pharma, ADF Foods and SJS Enterprises
- November 5, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Natco Pharma, ADF Foods and SJS Enterprises: ROE of 15.4% to 19.7% and FY22 to FY26 revenue CAGR of 13.0% to 27.0%. Prices as of 4 Nov 2026.
Quick Answer
The three cancer drug, ready meal and vehicle part stocks to watch are Natco Pharma, ADF Foods and SJS Enterprises. Their return on equity ranges from 15.4% to 19.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 13.0% to 27.0%. SJS Enterprises leads on both return on equity at 19.7% and revenue growth at 27.0% a year. Prices are based on the 4 November 2026 close, and this article is educational, not investment advice.
Cancer drug, ready meal and vehicle part stocks give investors a way to track businesses that sit close to everyday demand in India. Natco Pharma, ADF Foods and SJS Enterprises cover a complex generics maker, a ready to eat meals maker and a decorative auto parts maker.
This list covers three cancer drug, ready meal and vehicle part stocks with complete current figures: Natco Pharma, ADF Foods and SJS Enterprises. Every figure comes from the latest reported financials and the 4 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Cancer Drug, Ready Meal and Vehicle Part Stocks?
Cancer drug, ready meal and vehicle part stocks are listed companies that make complex generic and oncology medicines, sell ready-to-eat Indian meals, sauces and pickles overseas, and produce decorative lenses, badges and aesthetic parts for vehicles. Their earnings depend on drug approvals, food exports and vehicle output.
Cancer Drug, Ready Meal and Vehicle Part Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Natco Pharma | 788.75 | 15,708 | 13.7 | 36.0 | 15.4 | 0.08 |
| ADF Foods | 263.7 | 2,900 | 31.5 | 33.9 | 15.7 | 0.02 |
| SJS Enterprises | 2,156.3 | 6,459 | 30.5 | 36.9 | 19.7 | 0.03 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing cancer drug, ready meal and vehicle part stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in cancer drug, ready meal and vehicle part stocks can use the coming numbers to test whether growth is holding.
Why Do Cancer Drug, Ready Meal and Vehicle Part Stocks Have a Strong Roadmap in India?
Cancer drug, ready meal and vehicle part stocks have a strong roadmap in India because growing demand for specialised medicines, rising overseas sales of Indian food and steady vehicle output keep widening the market for these companies.
- Complex generics. Specialised medicines need skilled makers.
- Ready meals. Overseas shoppers buy more Indian food.
- Decorative parts. Premium vehicles use more aesthetic parts.
Why Natco Pharma Features Among These Cancer Drug, Ready Meal and Vehicle Part Stocks
Among the cancer drug, ready meal and vehicle part stocks on this list, Natco Pharma is a Hyderabad-based pharmaceutical company focused on complex generics, oncology, and active ingredients, with a significant presence in the United States and other regulated markets.
Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%.
The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0.
Roadmap: The company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.
What to watch: Check the timing of key product launches in the US and the contribution from new drug approvals.
Why ADF Foods Features Among These Cancer Drug, Ready Meal and Vehicle Part Stocks
Among the pharma, food and auto part shares on this list, ADF Foods, based in Gujarat, makes ready-to-eat Indian meals, sauces, pickles and frozen foods, and sells brands such as Ashoka and Camel in India and overseas.
The company has a return on equity of 15.7%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 2,900 crore. The stock trades at a P/E of 31.5, below the industry P/E of 33.9.
Revenue rose from Rs 431 crore in FY22 to Rs 703 crore in FY26, a compound annual growth rate of 13.0%. Net profit grew from Rs 48.5 crore in FY22 to Rs 89.9 crore in FY26, which works out to a compound annual growth rate of 16.7%. In the June 2026 quarter, revenue grew 23.9% year on year to Rs 168 crore, while net profit rose 13.5% to Rs 17.3 crore.
Roadmap: Indian food demand abroad, driven by the diaspora and global interest in ethnic cuisine, supports its exports. The company is also growing its domestic brand presence and its ready-to-eat range.
What to watch: Monitor shipping costs and export demand in its main markets.
Why SJS Enterprises Features Among These Cancer Drug, Ready Meal and Vehicle Part Stocks
Among the three companies on this list, SJS Enterprises makes decorative aesthetic parts such as lenses, badges, decals and appliqués for vehicles, along with products for consumer durables.
Revenue rose from Rs 374 crore in FY22 to Rs 973 crore in FY26, a compound annual growth rate of 27.0%. Net profit grew from Rs 55.0 crore in FY22 to Rs 172 crore in FY26, which works out to a compound annual growth rate of 32.9%.
In the June 2026 quarter, revenue grew 25.3% year on year to Rs 266 crore, while net profit rose 115.0% to Rs 74.4 crore. The company has a return on equity of 19.7%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 6,459 crore. The stock trades at a P/E of 30.5, below the industry P/E of 36.9.
Roadmap: Premium finishes, electric vehicle styling and a rising number of parts per vehicle widen its addressable market. The company has also acquired overseas and domestic businesses, which deepen its product range and customer mix.
What to watch: Follow how newly acquired units are integrated and how premium finishes contribute to the mix.
Natco Pharma vs ADF Foods vs SJS Enterprises on Key Financials
The table below sets the three cancer drug, ready meal and vehicle part stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Natco Pharma | 2,044 | 4,376 | 21.0% | 1,372 | 31.4% |
| ADF Foods | 431 | 703 | 13.0% | 89.9 | 12.8% |
| SJS Enterprises | 374 | 973 | 27.0% | 172 | 17.7% |
SJS Enterprises posts the highest return on equity in this group at 19.7%. Natco Pharma has the largest FY26 revenue at Rs 4,376 crore, and SJS Enterprises shows the fastest revenue growth with a 27.0% compound annual rate. A useful habit with cancer drug, ready meal and vehicle part stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Cancer Drug, Ready Meal and Vehicle Part Stocks
Every theme carries risks that deserve a check before any decision. For these cancer drug, ready meal and vehicle part stocks, the main points are: Long-term pharma, food and auto part shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Currency moves. Export earnings move with the rupee.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter cancer drug, ready meal and vehicle part stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Cancer Drug, Ready Meal and Vehicle Part Stocks
Cancer drug, ready meal and vehicle part stocks work best when investors track growth, valuation and return on equity side by side. Natco Pharma, ADF Foods and SJS Enterprises each have a clear plan to grow. Based on the 4 November 2026 close, Natco Pharma trades at Rs 788.75, ADF Foods at Rs 263.7 and SJS Enterprises at Rs 2,156.3. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these cancer drug, ready meal and vehicle part stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track cancer drug, ready meal and vehicle part stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are cancer drug, ready meal and vehicle part stocks?
Ans. Cancer drug, ready meal and vehicle part stocks are listed companies that make complex generic and oncology medicines, sell ready-to-eat Indian meals, sauces and pickles overseas, and produce decorative lenses, badges and aesthetic parts for vehicles. Their earnings depend on drug approvals, food exports and vehicle output. This list looks at three of them, Natco Pharma, ADF Foods and SJS Enterprises, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.
Which cancer drug, ready meal and vehicle part stocks are covered in this list?
Ans. This list covers Natco Pharma, ADF Foods and SJS Enterprises. Based on the 4 November 2026 close, Natco Pharma traded at Rs 788.75, ADF Foods at Rs 263.7 and SJS Enterprises at Rs 2,156.3. Their return on equity ranges from 15.4% to 19.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 13.0% to 27.0%.
Why do cancer drug, ready meal and vehicle part stocks have a strong future roadmap in India?
Ans. Cancer drug, ready meal and vehicle part stocks have a strong roadmap in India because growing demand for specialised medicines, rising overseas sales of Indian food and steady vehicle output keep widening the market for these companies. The main drivers are as follows. Complex generics. Specialised medicines need skilled makers. Ready meals. Overseas shoppers buy more Indian food. Decorative parts. Premium vehicles use more aesthetic parts. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Natco Pharma performed financially?
Ans. Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.
How has ADF Foods performed financially?
Ans. Revenue rose from Rs 431 crore in FY22 to Rs 703 crore in FY26, a compound annual growth rate of 13.0%. Net profit grew from Rs 48.5 crore in FY22 to Rs 89.9 crore in FY26, which works out to a compound annual growth rate of 16.7%. In the June 2026 quarter, revenue grew 23.9% year on year to Rs 168 crore, while net profit rose 13.5% to Rs 17.3 crore. The company has a return on equity of 15.7%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 2,900 crore. The stock trades at a P/E of 31.5, below the industry P/E of 33.9. Looking ahead, indian food demand abroad, driven by the diaspora and global interest in ethnic cuisine, supports its exports. The company is also growing its domestic brand presence and its ready-to-eat range.
How has SJS Enterprises performed financially?
Ans. Revenue rose from Rs 374 crore in FY22 to Rs 973 crore in FY26, a compound annual growth rate of 27.0%. Net profit grew from Rs 55.0 crore in FY22 to Rs 172 crore in FY26, which works out to a compound annual growth rate of 32.9%. In the June 2026 quarter, revenue grew 25.3% year on year to Rs 266 crore, while net profit rose 115.0% to Rs 74.4 crore. The company has a return on equity of 19.7%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 6,459 crore. The stock trades at a P/E of 30.5, below the industry P/E of 36.9. Looking ahead, premium finishes, electric vehicle styling and a rising number of parts per vehicle widen its addressable market. The company has also acquired overseas and domestic businesses, which deepen its product range and customer mix.
What risks should investors check before buying cancer drug, ready meal and vehicle part stocks?
Ans. Investors should check a few risks before buying cancer drug, ready meal and vehicle part stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of cancer drug, ready meal and vehicle part stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.